Pliant Therapeutics Future Growth
Future criteria checks 2/6
Pliant Therapeutics's earnings are forecast to decline at 8.9% per annum while its annual revenue is expected to grow at 43.1% per year. EPS is expected to decline by 0.8% per annum. Return on equity is forecast to be -56.1% in 3 years.
Key information
-8.9%
Earnings growth rate
-0.8%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 43.1% |
| Future return on equity | -56.1% |
| Analyst coverage | Good |
| Last updated | 27 Apr 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 7 | -200 | -202 | -201 | 10 |
| 12/31/2024 | 2 | -178 | -172 | -171 | 10 |
| 12/31/2023 | 3 | -155 | -136 | -135 | 12 |
| 12/31/2022 | 10 | -123 | -96 | -95 | N/A |
| 9/30/2022 | 10 | -113 | -85 | -83 | N/A |
| 6/30/2022 | 10 | -109 | -89 | -87 | N/A |
| 3/31/2022 | 7 | -103 | -85 | -82 | N/A |
| 12/31/2021 | 8 | -97 | -77 | -75 | N/A |
| 9/30/2021 | 10 | -92 | -74 | -72 | N/A |
| 6/30/2021 | 13 | -81 | -67 | -65 | N/A |
| 3/31/2021 | 15 | -75 | -40 | -38 | N/A |
| 12/31/2020 | 42 | -42 | -39 | -37 | N/A |
| 9/30/2020 | 94 | 18 | 15 | 16 | N/A |
| 6/30/2020 | 90 | 19 | 16 | 17 | N/A |
| 3/31/2020 | 86 | 20 | -6 | -5 | N/A |
| 12/31/2019 | 57 | -7 | -4 | -3 | N/A |
| 3/31/2019 | N/A | -43 | -33 | -32 | N/A |
| 12/31/2018 | N/A | -35 | -31 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9PT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9PT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9PT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9PT's revenue (43.1% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 9PT's revenue (43.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9PT is forecast to be unprofitable in 3 years.